keyword
MENU ▼
Read by QxMD icon Read
search

Lymphoma transplant

keyword
https://www.readbyqxmd.com/read/28717086/therapy-related-acute-myeloid-leukemia-after-the-long-term-administration-of-low-dose-etoposide-for-chronic-type-adult-t-cell-leukemia-lymphoma-a-case-report-and-literature-review
#1
Naoki Shimada, Nobuhiro Ohno, Ryuji Tanosaki, Shigeo Fuji, Yuhko Suzuki, Koichiro Yuji, Kaoru Uchimaru, Arinobu Tojo
A 61-year-old woman with chronic-type adult T-cell leukemia-lymphoma (ATL) had been taking low-dose oral etoposide for progressive lymphocytosis. After taking this for 3.5 years, she was diagnosed with therapy-related acute myeloid leukemia (t-AML), with a chromosomal translocation of t (6:11) (q27; q23). She thus received remission induction therapy, consolidation therapy, and allogeneic hematopoietic stem cell transplantation. Although both t-AML and ATL were in remissive states, she died of a therapy-related infection within 1 year...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28717085/high-dose-chemotherapy-with-stem-cell-rescue-provided-durable-remission-for-classical-hodgkin-lymphoma-type-post-transplant-lymphoproliferative-disorder-after-unrelated-cord-blood-transplantation-a-case-report-and-review-of-the-literature
#2
Hidehiro Itonaga, Takeharu Kato, Machiko Fujioka, Masataka Taguchi, Hiroaki Taniguchi, Yoshitaka Imaizumi, Shinichiro Yoshida, Hiroaki Miyoshi, Yukiyoshi Moriuchi, Koichi Ohshima, Yasushi Miyazaki
An adult woman developed polymorphic post-transplant lymphoproliferative disorder (PTLD) 58 months after unrelated cord blood transplantation. She was treated successfully with chemotherapy and radiation therapy but presented with lymphadenopathy and splenomegaly 74 months after transplantation. A lymph node biopsy confirmed the diagnosis of nodular sclerosis type Hodgkin lymphoma (classical Hodgkin lymphoma [CHL]-type PTLD). After salvage therapy and hematopoietic stem cell harvesting, she was subsequently treated with consolidative high-dose chemotherapy with melphalan followed by stem cell rescue, which resulted in durable remission...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28711575/how-to-approach-a-patient-with-limited-stage-hodgkin-lymphoma-who-remains-pet-positive-at-the-end-of-chemotherapy-radiation-therapy
#3
REVIEW
Nmazuo W Ozuah, Ann S LaCasce
The use of 18-F fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography has emerged as a crucial tool for response-adapted therapy in Hodgkin lymphoma (HL). Although more studies have focused on the predictive value of an interim or early PET obtained after 2 cycles of chemotherapy, there are indications that the end of therapy PET might even be more predictive of outcome. The optimal treatment of patients with limited stage HL who are PET-positive after chemotherapy is unknown...
June 29, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28701859/advances-in-the-pathophysiology-and-treatment-of-relapsed-refractory-hodgkin-s-lymphoma-with-an-emphasis-on-targeted-therapies-and-transplantation-strategies
#4
Theodoros Karantanos, Ioannis Politikos, Vassiliki A Boussiotis
Hodgkin's lymphoma (HL) is highly curable with first-line therapy. However, a minority of patients present with refractory disease or experience relapse after completion of frontline treatment. These patients are treated with salvage chemotherapy followed by autologous stem cell transplantation (ASCT), which remains the standard of care with curative potential for refractory or relapsed HL. Nevertheless, a significant percentage of such patients will progress after ASCT, and allogeneic hematopoietic stem cell transplantation remains the only curative approach in that setting...
2017: Blood and Lymphatic Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28701367/a-fdg-pet-driven-consolidation-strategy-in-diffuse-large-b-cell-lymphoma-final-results-of-a-randomized-phase-ii-study
#5
Rene-Olivier Casasnovas, Loic Ysebaert, Catherine Thieblemont, Emmanuel Bachy, Pierre Feugier, Alain Delmer, Sabine Tricot, Jean Gabarre, Marc Andre, Christophe Fruchart, Nicolas Mounier, Richard Delarue, Michel Meignan, Alina Berriolo-Riedinger, Stephane Bardet, Jean-Francois Emile, Jean-Philippe Jais, Corinne Haioun, Herve Tilly, Franck Morschhauser
Dose-dense induction and upfront consolidation with autologous stem cell transplantation (ASCT) remain controversial issues when treating high-risk diffuse large B cell lymphoma patients. GELA designed a randomized phase II trial evaluating the efficacy of either R-ACVBP or R-CHOP14 induction and a PET-driven ASCT or standard immunochemotherapy (SIC) consolidation in aaIPI2-3 patients. PET was done at baseline, after 2 (PET2) and 4 induction cycles (PET4) and centrally assessed using international harmonization project (IHP) criteria...
July 12, 2017: Blood
https://www.readbyqxmd.com/read/28699897/posttransplant-lymphoproliferative-disorders-in-kidney-transplant-recipients-a-retrospective-cohort-analysis-over-two-decades-in-hong-kong
#6
Chi Yuen Cheung, Maggie Kam Man Ma, Ka Foon Chau, Wai Leung Chak, Sydney Chi Wai Tang
OBJECTIVE: To characterize the posttransplant lymphoproliferative disorders (PTLD) including the Epstein-Barr virus (EBV) status, histological subgroups, site of occurrence and the clinical outcome in the Chinese kidney transplant recipients. METHODS: A retrospective cohort study of 1, 227 adult kidney transplant recipients who were followed up in two transplant centers in Hong Kong over two decades. RESULTS: 23 (1.9%) patients developed PTLD...
June 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/28699667/mantle-cell-lymphoma-2017-update-on-diagnosis-risk-stratification-and-clinical-management
#7
Julie M Vose
DISEASE OVERVIEW: Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a short remission duration to standard therapies and a median overall survival (OS) of 4-5 years. DIAGNOSIS: Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t (11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1...
August 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28698751/analysis-of-factors-that-influence-hematopoietic-recovery-in-autologous-transplanted-patients-with-hematopoietic-stem-cells-from-peripheral-blood
#8
Rada M Grubovic, Borce Georgievski, Lidija Cevreska, Sonja Genadieva-Stavric, Milos R Grubovic
BACKGROUND: Successful hematopoietic stem cell transplantation (HSCT) requires a rapid and durable hematopoietic recovery. AIM: The aim of our study was to analyse factors that influence hematopoietic recovery after autologous HSCT. MATERIALS AND METHODS: Multiple regression analysis was used to analyse factors affecting neutrophil and platelet engraftment in 90 autologous transplanted patients - 30 with acute myeloid leukaemia (AML), 30 with lymphoma and 30 with multiple myeloma (MM) from 2008 till 2016...
June 15, 2017: Open Access Macedonian Journal of Medical Sciences
https://www.readbyqxmd.com/read/28697656/impact-of-liver-transplantation-on-the-risk-of-second-malignant-tumors-among-hepatocellular-carcinoma-patients
#9
Hani Oweira, Jan Schmidt, Daniel Helbling, Ulf Petrausch, Othmar Schöb, Arianeb Mehrabi, Anwar Giryes, Hazem Elhadedy, Omar Abdel-Rahman
BACKGROUND: Population-based data on the development of second malignant neoplasms (SMNs) following the diagnosis of hepatocellular carcinoma (HCC) are uncommon. We evaluated this clinical vignette in HCC patients within the Surveillance, Epidemiology and End Results (SEER) database. METHODS: The SEER database (1973-2012) was queried using the SEER*Stat program to determine the clinico-pathological features of HCC patients with more than one year survival who developed SMNs...
July 12, 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28696028/pretransplant-functional-imaging-and-outcome-in-pediatric-patients-with-relapsed-refractory-hodgkin-lymphoma-undergoing-autologous-transplantation
#10
Nmazuo W Ozuah, Hisham M Dahmoush, Frederick D Grant, Leslie E Lehmann, Ann S LaCasce, Amy L Billett, Steven P Margossian
BACKGROUND: Pretransplant functional imaging (FI), particularly a negative positron emission tomography (PET), is a strong predictor of outcome in adults with relapsed or refractory Hodgkin lymphoma (HL), but data in pediatrics are limited. METHODS: The medical records of 49 consecutive pediatric patients, who received autologous transplant at a single institution, were retrospectively analyzed. All patients had either gallium or PET scan before transplant and were conditioned with carmustine, etoposide, cytarabine, and melphalan (BEAM)...
July 11, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28693234/relapsed-anaplastic-lymphoma-kinase-positive-large-b-cell-lymphoma-expressed-cluster-of-differentiation-4-and-cytokeratin-an-initially-misdiagnosed-case-corrected-by-immunoglobulin-%C3%AE%C2%BA-locus-gene-rearrangement-detection
#11
Yunfei Shi, Xianghong Li, Yuqin Song, Lixin Zhou, Qin Feng, Ping Wang, Chen Zhang, Weiping Liu, Yanhua Bai, Yumei Lai
Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL) is a rare lymphoma subtype. The present study investigated a refractory nodal ALK-positive LBCL case in a 28-year-old Chinese male. It was initially misdiagnosed as ALK-positive anaplastic large cell lymphoma; however, the patient's lesions relapsed and spread widely following a short remission for chemotherapy and the patient succumbed to the disease 3 months' post-autologous stem cell transplantation; thus, a revision was performed. Histologically, the tumor cells exhibited a characteristic immunoblastic morphology with marked cellular pleomorphism...
July 2017: Oncology Letters
https://www.readbyqxmd.com/read/28692029/pre-autologous-transplantation-pet-ct-using-deauville-criteria-is-an-independent-predictor-of-progression-in-relapsed-refractory-classical-hodgkin-lymphoma
#12
M Damlaj, S Ghazi, G Syed, T Pasha, G Gmati, H Salama, O Ali, K A Abuelgasim, M Al-Zahrani, A Hejazi, A Al Askar
No abstract text is available yet for this article.
July 10, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28687959/stem-cell-therapy-for-fanconi-anemia
#13
Qing-Shuo Zhang
Stem cell therapy is the administration of stem cells to a patient to treat or prevent a disease. Since stem cells possess the long-term self-renewal capacity and provide daughter cells that differentiate into the specialized cells of each tissue, stem cell therapy will theoretically improve the disease condition for the lifetime of the patient. As the most widely used stem cell therapy, bone marrow transplantation is the treatment of choice for many kinds of blood disorders, including anemias, leukemias, lymphomas, and rare immunodeficiency diseases...
July 8, 2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28685308/pseudo-autologous-stem-cell-transplantation-for-donor-derived-mantle-cell-lymphoma-12%C3%A2-years-after-allogeneic-transplantation
#14
Masaharu Tamaki, Hidenori Wada, Ayumi Gomyo, Jin Hayakawa, Yu Akahoshi, Naonori Harada, Machiko Kusuda, Yuko Ishihara, Koji Kawamura, Aki Tanihara, Miki Sato, Kiriko Terasako-Saito, Kazuaki Kameda, Misato Kikuchi, Shun-Ichi Kimura, Hideki Nakasone, Shinichi Kako, Yoshinobu Kanda
Donor-derived malignancy is a rare morbidity after allogeneic hematopoietic stem cell transplantation (HSCT), in which most previous cases have presented as acute leukemia or myelodysplastic syndrome. There have, however, been very few reports of donor-derived lymphoma. Here, we present a case of donor-derived mantle cell lymphoma 12 years after allogeneic HSCT, which was successfully treated with chemotherapy followed by pseudo-autologous HSCT (pASCT), i.e., an autologous HSC transplant following allogeneic HSCT in which the infused stem cell is considered to be derived from the donor cells...
July 6, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28680340/successful-treatment-of-pulmonary-candidiasis-and-aspergillosis-in-patient-with-refractory-hodgkin-lymphoma-using-micafungin-case-study-and-brief-literature-review
#15
Marta Barańska, Renata Kroll-Balcerzak, Lidia Gil, Joanna Rupa-Matysek, Mieczysław Komarnicki
The number of patients with hematological malignancies who develop invasive fungal disease (IFD) has increased dramatically in recent decades. This increase is attributed to impairment of the host immune system due to intensive cytotoxic chemotherapies, use of corticosteroids and profound immunosuppression after hematopoietic stem cell transplantation (HSCT). Additionally, the increasing prevalence of fungal infections caused by emerging and rare pathogens, IFD of mixed etiology or of atypical localization is observed...
2017: Central-European Journal of Immunology
https://www.readbyqxmd.com/read/28680001/progress-in-the-management-of-atl
#16
Kenji Ishitsuka
Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy caused by human T-lymphotropic virus type I (HTLV-1), and its prognosis remains poor. Three to five percent of HTLV-1 carriers, infected mainly by breast feeding, develop ATL after a latency period as long as 70 years. The standard of care for aggressive ATL and indolent ATL comprises intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation, if applicable, and watchful waiting, respectively. Outside Japan, a combination of interferon-α and zidovudine has also been used as a therapeutic option for acute, chronic, and smoldering-type ATLs...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28679969/incidence-of-spontaneous-lymphomas-in-non-experimental-nod-shi-scid-il-2r%C3%AE-null-nog-mice
#17
Masahiko Yasuda, Tomoyuki Ogura, Takayuki Goto, Mika Yagoto, Yoko Kamai, Chie Shimomura, Nobuhito Hayashimoto, Yukito Kiyokawa, Hideki Shinohara, Riichi Takahashi, Kenji Kawai
Severely immunodeficient NOD/Shi-scid, IL-2Rγ(null) (NOG) mice provide an in vivo model for human cell/tissue transplantation studies. NOG mice were established by combining interleukin-2 receptor-γ chain knockout mice and NOD/Shi-scid mice. They exhibit a high incidence of thymic lymphomas and immunoglobulin (Ig) leakiness. In this study, we assessed the incidence of malignant lymphomas and the occurrence of leakiness in 2,184 non-experimental NOG retired breeder mice aged 16-40 weeks. We established that the total incidence of lymphomas was only 0...
July 6, 2017: Experimental Animals
https://www.readbyqxmd.com/read/28668466/recommendations-for-screening-monitoring-prevention-prophylaxis-and-therapy-of-hepatitis-b-virus-reactivation-in-patients-with-haematological-malignancies-and-patients-who-underwent-haematological-stem-cell-transplantation-a-position-paper
#18
L Sarmati, M Andreoni, G Antonelli, W Arcese, R Bruno, N Coppola, G B Gaeta, M Galli, C Girmenia, M Mikulska, F Pane, C F Perno, M Picardi, M Puoti, A Rambaldi, V Svicher, G Taliani, G Gentile
SCOPE: Hepatitis B virus (HBV) infection reactivation is associated with high morbidity and mortality in patients with haematological malignancy and/or haematopoietic stem cell transplantation (HSCT) however information on this issue is limited. The scope of this position paper is to provide recommendations on HBV screening, monitoring, prophylaxis, treatment and vaccination in the patients described above. METHODS: - These recommendations were developed from one meeting of experts attended by different Italian scientific societies as well as from a systematic literature review (through December 31, 2016) on HBV infection in haematological patients and in patients who underwent HSCT published in the same issue of this journal...
June 28, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28668465/screening-monitoring-prevention-prophylaxis-and-therapy-for-hepatitis-b-virus-reactivation-in-patients-with-haematological-malignancies-and-patients-who-underwent-haematological-stem-cell-transplantation-a-systematic-review
#19
REVIEW
G Gentile, M Andreoni, G Antonelli, L Sarmati
BACKGROUND: The growth of new therapeutic options and practices increases the risk of Hepatitis B virus (HBV) reactivation in patients with haematological malignancies and/or patients undergoing haematological stem cell transplantation (HSCT). OBJECTIVES: To provide a systematic review supporting recommendations for prevention, monitoring, prophylaxis and therapy of HBV reactivation in patients with haematological malignancies and HSCT. DATA SOURCES: The systematic review was based on a search strategy using PubMed and the Cochrane Library from 1991 to December 31(,) 2016...
June 28, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28668386/rituximab-dose-dense-chemotherapy-with-or-without-high-dose-chemotherapy-plus-autologous-stem-cell-transplantation-in-high-risk-diffuse-large-b-cell-lymphoma-dlcl04-final-results-of-a-multicentre-open-label-randomised-controlled-phase-3-study
#20
Annalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, Ercole Brusamolino, Andrea Evangelista, Angelo Michele Carella, Caterina Stelitano, Giuseppe Rossi, Monica Balzarotti, Francesco Merli, Gianluca Gaidano, Vincenzo Pavone, Luigi Rigacci, Francesco Zaja, Alfonso D'Arco, Nicola Cascavilla, Eleonora Russo, Alessia Castellino, Manuel Gotti, Angela Giovanna Congiu, Maria Giuseppina Cabras, Alessandra Tucci, Claudio Agostinelli, Giovannino Ciccone, Stefano A Pileri, Umberto Vitolo
BACKGROUND: The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is poor. The aim of this study was to investigate the possible benefit of intensification with high-dose chemotherapy and autologous stem-cell transplantation as part of first-line treatment in these patients. METHODS: We did a multicentre, open-label, randomised, controlled, phase 3 trial with a 2 × 2 factorial design to compare, at two different R-CHOP dose levels, a full course of rituximab-dose-dense chemotherapy (no transplantation group) versus an abbreviated course of rituximab-dose-dense chemotherapy followed by consolidation with R-MAD (rituximab plus high-dose cytarabine plus mitoxantrone plus dexamethasone) and high-dose BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) plus autologous stem-cell transplantation (transplantation group) in young patients (18-65 years) with untreated high-risk diffuse large B-cell lymphoma (aa-IPI score 2-3)...
June 28, 2017: Lancet Oncology
keyword
keyword
7304
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"